datopotamab deruxtecan   Click here for help

GtoPdb Ligand ID: 13304

Synonyms: Dato-DXd | datopotamab deruxtecan-dlnk | Datroway® | DS-1062 | DS-1062a
Approved drug
datopotamab deruxtecan is an approved drug (FDA (2025))
Compound class: Antibody
Comment: Datopotamab deruxtecan is an anti-TROP2 (TACSTD2) antibody drug conjugate (ADC). The cytotoxic payload is an exatecan-derived topoisomerase I inhibitor known as deruxtecan (DXd/MAAA1181a; PubChem CID 118305111). The ADC is highly stable in circulation and the DXd is only cleaved once inside cells where it induces DNA damage and apoptosis.

Overexpression of TROP2 is oncogenic and drives proliferation in cancer cells.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2025)
International Nonproprietary Names Click here for help
INN number INN
11218 datopotamab deruxtecan
Synonyms Click here for help
Dato-DXd | datopotamab deruxtecan-dlnk | Datroway® | DS-1062 | DS-1062a
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1006
Other databases
GtoPdb PubChem SID 496703274
Search PubMed clinical trials datopotamab deruxtecan
Search PubMed titles datopotamab deruxtecan
Search PubMed titles/abstracts datopotamab deruxtecan